RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors

Exclusion Criteria

• •1. Those who have received major surgery, conventional chemotherapy, large-area radiotherapy, immunotherapy or biological therapy anti-tumor treatment within 4 weeks before entering the trial;
• •2. Previous use of drugs targeting KRAS G12V mutations, including previous participation in cell therapy with similar targets Cellular testing and small molecule inhibitors targeting KRAS G12V mutations, etc.;
• •3. Allergic reactions are known to occur to any ingredient (such as dimethyl sulfoxide, cyclophosphamide, fludarabine) or structurally similar compounds treated in this trial;
• •4. Failure to recover from adverse reactions related to previous surgery or treatment to \< Grade 2 CTCAEV5.0;
• •5. Hypertension that remains uncontrolled after combined treatment with 2 drugs or clinically significant (such as active) Cardiovascular and cerebrovascular diseases, such as cerebrovascular accident (within 6 months before signing the informed consent form), myocardial infarction (within 6 months before signing the informed consent form), unstable angina, congestive heart failure classified as class II or above by the New York Heart Association, or severe arrhythmia that cannot be controlled with medication or has a potential impact on study treatment; the electrocardiogram showed obvious abnormality or average QTc interval ≧ 450ms for 3 consecutive times (at least 5 minutes interval);
• •6. Combined with other serious organic diseases and mental disorders;
• •7. Suffering from systemic active infections requiring treatment, including but not limited to active tuberculosis, known HIV positive patients or patients with clinically active hepatitis A, B, or C include virus carriers;
• •8. Have a history of inflammatory bowel disease and autoimmune diseases judged by the researcher to be unsuitable for this study (such as systemic lupus erythematosus, vasculitis, etc.);
• •9. Those who plan to use the following drugs within 4 weeks before cell therapy and during the study: long-term systemic use steroid hormones, hydroxyurea, immunomodulatory drugs (such as interleukin 2, alpha or gamma interferon, GM-CSF, mTOR inhibitors, cyclosporins, thymosin, etc.);
• •10. People with brain metastasis:
• •1. Symptomatic brain metastasis should be ruled out. Patients with a previous history of symptomatic brain metastasis and stable symptoms after local treatment were enrolled in the group who did not need antiepileptic drugs and steroids at least 14 days before lymphocyte clearance.
• •2. Subjects with asymptomatic brain metastasis without tumor-related brain edema, displacement, steroids or antiepileptic drugs can be enrolled.
• •3. Subjects with meningitis or meningeal metastasis need to be excluded.
• •11. People with bleeding or thromboembolism tendency:
• •1. Have clinically significant bleeding symptoms or obvious bleeding tendency within 2 weeks before the study;
• •2. Have inherited or acquired bleeding and thrombosis tendencies;
• •3. A serious arterial/venous thromboembolic event within the past 6 months.
• •12. Suffering from massive pericardial effusion or symptomatic thoracic or abdominal effusion;
• •13. Have received live attenuated vaccines within 4 weeks before cell infusion, or plan to receive this type of vaccine during the study;
• •14. History of organ allogeneic transplantation, allogeneic stem cell transplantation and renal replacement therapy;
• •15. Uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure;
• •16. Known alcohol and/or drug abusers;
• •17. Pregnant or breastfeeding women;
• •18. Have any coexisting medical conditions or diseases that the researcher determines may impair the conduct of this trial subjects;
• •19. No legal capacity/restricted capacity;
• •20. Have previously received any gene or cell therapy products.